{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:12:13Z","timestamp":1773828733016,"version":"3.50.1"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.bone.2016.10.018","type":"journal-article","created":{"date-parts":[[2016,10,22]],"date-time":"2016-10-22T06:15:44Z","timestamp":1477116944000},"page":"18-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Application of anti-Sclerostin therapy in non-osteoporosis disease models"],"prefix":"10.1016","volume":"96","author":[{"given":"Christina M.","family":"Jacobsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bone.2016.10.018_bb0005","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.bone.2016.10.018_bb0010","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor-related protein 5","volume":"346","author":"Boyden","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2016.10.018_bb0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","article-title":"A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait","volume":"70","author":"Little","year":"2002","journal-title":"Am. J. Hum. Genet."},{"issue":"6","key":"10.1016\/j.bone.2016.10.018_bb0020","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00223-008-9130-9","article-title":"The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations","volume":"82","author":"Balemans","year":"2008","journal-title":"Calcif. Tissue Int."},{"issue":"20","key":"10.1016\/j.bone.2016.10.018_bb0025","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"50","key":"10.1016\/j.bone.2016.10.018_bb0030","doi-asserted-by":"crossref","first-page":"38276","DOI":"10.1074\/jbc.M609509200","article-title":"LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST","volume":"281","author":"Semenov","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bone.2016.10.018_bb0035","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/jbmr.2514","article-title":"High bone mass-causing mutant LRP5 receptors are resistant to endogenous inhibitors in vivo","volume":"30","author":"Niziolek","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.10.018_bb0040","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.bone.2016.10.018_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","author":"Balemans","year":"2002","journal-title":"J. Med. Genet."},{"issue":"5","key":"10.1016\/j.bone.2016.10.018_bb0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/jmedgenet-2013-101567","article-title":"Mutations in WNT1 are a cause of Osteogenesis Imperfecta","volume":"50","author":"Fahiminiya","year":"2013","journal-title":"J. Med. Genet."},{"issue":"19","key":"10.1016\/j.bone.2016.10.018_bb0055","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1215458","article-title":"WNT1 mutations in early-onset osteoporosis and Osteogenesis Imperfecta","volume":"368","author":"Laine","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bone.2016.10.018_bb0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ajhg.2013.02.010","article-title":"Mutations in WNT1 cause different forms of bone fragility","volume":"92","author":"Keupp","year":"2013","journal-title":"Am. J. Hum. Genet."},{"issue":"33","key":"10.1016\/j.bone.2016.10.018_bb0065","doi-asserted-by":"crossref","first-page":"23698","DOI":"10.1074\/jbc.M601000200","article-title":"The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment","volume":"281","author":"Sawakami","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bone.2016.10.018_bb0070","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bone.2016.10.018_bb0075","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nm.2388","article-title":"Lrp5 functions in bone to regulate bone mass","volume":"17","author":"Cui","year":"2011","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bone.2016.10.018_bb0080","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.10.018_bb0085","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2016.10.018_bb0090","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1210\/en.2013-1905","article-title":"Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26weeks of treatment with a sclerostin antibody","volume":"155","author":"Li","year":"2014","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.bone.2016.10.018_bb0095","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2016.10.018_bb0100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.bone.2016.10.018_bb0105","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bone.2016.10.018_bb0110","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.bone.2016.10.018_bb0115","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.2489","article-title":"The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density","volume":"30","author":"Recknor","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.10.018_bb0120","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","author":"Genant","year":"2016","journal-title":"J. Bone Miner. Res"},{"key":"10.1016\/j.bone.2016.10.018_bb0125","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.bone.2016.10.018_bb0130","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jbmr.2152","article-title":"Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody","volume":"29","author":"Ominsky","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2016.10.018_bb0135","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bone.2010.09.009","article-title":"Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model","volume":"48","author":"Tian","year":"2011","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2016.10.018_bb0140","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00223-012-9610-9","article-title":"Early response of bone marrow osteoprogenitors to skeletal unloading and sclerostin antibody","volume":"91","author":"Shahnazari","year":"2012","journal-title":"Calcif. Tissue Int."},{"issue":"4","key":"10.1016\/j.bone.2016.10.018_bb0145","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jbmr.1807","article-title":"Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading","volume":"28","author":"Spatz","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2016.10.018_bb0150","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/jbmr.2549","article-title":"Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats","volume":"30","author":"Qin","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2016.10.018_bb0155","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jbmr.2396","article-title":"Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss","volume":"30","author":"Beggs","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2016.10.018_bb0160","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1742-7843.2004.pto940602.x","article-title":"Teriparatide (biosynthetic human parathyroid hormone 1\u201334): a new paradigm in the treatment of osteoporosis","volume":"94","author":"Brixen","year":"2004","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"211","key":"10.1016\/j.bone.2016.10.018_bb0165","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006627","article-title":"Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome","volume":"5","author":"Kedlaya","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bone.2016.10.018_bb0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jbmr.2059","article-title":"Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity","volume":"29","author":"Chang","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2016.10.018_bb0175","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00223-012-9588-3","article-title":"Recent advances in Osteogenesis Imperfecta","volume":"90","author":"Cundy","year":"2012","journal-title":"Calcif. Tissue Int."},{"issue":"Suppl 2","key":"10.1016\/j.bone.2016.10.018_bb0180","first-page":"397","article-title":"Osteogenesis Imperfecta","volume":"10","author":"Ben Amor","year":"2013","journal-title":"Pediatr. Endocrinol. Rev."},{"issue":"14","key":"10.1016\/j.bone.2016.10.018_bb0185","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe Osteogenesis Imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2016.10.018_bb0190","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000381713","article-title":"Efficacy and safety of bisphosphonate therapy in children with Osteogenesis Imperfecta: a systematic review","volume":"84","author":"Rijks","year":"2015","journal-title":"Horm Res Paediatr."},{"key":"10.1016\/j.bone.2016.10.018_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005088.pub2","article-title":"Bisphosphonate therapy for Osteogenesis Imperfecta","volume":"4","author":"Phillipi","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.bone.2016.10.018_bb0200","first-page":"653","article-title":"Effect of intravenous pamidronate treatment in children with Osteogenesis Imperfecta","volume":"24","author":"Atta","year":"2014","journal-title":"Journal of the College of Physicians and Surgeons\u2013Pakistan : JCPSP."},{"issue":"5","key":"10.1016\/j.bone.2016.10.018_bb0205","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with Osteogenesis Imperfecta type I","volume":"93","author":"Gatti","year":"2013","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"10.1016\/j.bone.2016.10.018_bb0210","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with Osteogenesis Imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bone.2016.10.018_bb0215","first-page":"38","article-title":"Pamidronate treatment of children with moderate-to-severe Osteogenesis Imperfecta: a note of caution","volume":"71","author":"Alharbi","year":"2009","journal-title":"Horm. Res."},{"issue":"10","key":"10.1016\/j.bone.2016.10.018_bb0220","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of Osteogenesis Imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.10.018_bb0225","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bone.2016.06.005","article-title":"Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+\/mov13) mouse model of type I","volume":"90","author":"Jacobsen","year":"2016","journal-title":"Osteogenesis Imperfecta. Bone"},{"issue":"1","key":"10.1016\/j.bone.2016.10.018_bb0230","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of Osteogenesis Imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2016.10.018_bb0235","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ mouse model of Osteogenesis Imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2016.10.018_bb0240","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly growing Brtl\/+ mouse model of Osteogenesis Imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.10.018_bb0245","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe Osteogenesis Imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.10.018_bb0250","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap mice, a model of recessive Osteogenesis Imperfecta","author":"Grafe","year":"2015","journal-title":"J. Bone Miner. Res"},{"key":"10.1016\/j.bone.2016.10.018_bb0255","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bone.2016.04.011","article-title":"Bone mineral properties in growing Col1a2(+\/G610C) mice, an animal model of Osteogenesis Imperfecta","volume":"87","author":"Masci","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.10.018_bb0260","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2016.01.001","article-title":"Effect of anti-sclerostin therapy and Osteogenesis Imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age","volume":"84","author":"Sinder","year":"2016","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2016.10.018_bb0265","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/jmedgenet-2012-101307","article-title":"Osteogenesis Imperfecta type V: marked phenotypic variability despite the presence of the IFITM5 c.-14C>T mutation in all patients","volume":"50","author":"Rauch","year":"2013","journal-title":"J. Med. Genet."},{"issue":"4","key":"10.1016\/j.bone.2016.10.018_bb0270","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/14656566.2015.997709","article-title":"Management of osteoporosis in rheumatoid arthritis patients","volume":"16","author":"Hoes","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"issue":"23","key":"10.1016\/j.bone.2016.10.018_bb0275","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2016.10.018_bb0280","doi-asserted-by":"crossref","first-page":"18421","DOI":"10.1038\/srep18421","article-title":"Increased Dickkopf-1 in recent-onset rheumatoid arthritis is a new biomarker of structural severity. Data from the ESPOIR Cohort","volume":"6","author":"Seror","year":"2016","journal-title":"Sci. Report."},{"issue":"10","key":"10.1016\/j.bone.2016.10.018_bb0285","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1136\/annrheumdis-2013-203345","article-title":"Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis","volume":"72","author":"Chen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.bone.2016.10.018_bb0290","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar4305","article-title":"Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study","volume":"15","author":"Marenzana","year":"2013","journal-title":"Arthritis Research & Therapy."},{"issue":"330","key":"10.1016\/j.bone.2016.10.018_bb0295","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4351","article-title":"Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction","volume":"8","author":"Wehmeyer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bone.2016.10.018_bb0300","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2015.04.021","article-title":"Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions","volume":"77","author":"Newman","year":"2015","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2016.10.018_bb0305","first-page":"324","article-title":"The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder","volume":"24","author":"Costa","year":"2015","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"3","key":"10.1016\/j.bone.2016.10.018_bb0310","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jbmr.2372","article-title":"Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy","volume":"30","author":"Moe","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2016.10.018_bb0315","first-page":"1428","article-title":"Mechanisms of low bone mineral density in inflammatory bowel diseases","volume":"112","author":"Abitbol","year":"1997","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bone.2016.10.018_bb0320","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1756-185X.2010.01542.x","article-title":"The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases","volume":"13","author":"Ezzat","year":"2010","journal-title":"Int. J. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bone.2016.10.018_bb0325","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000092013","article-title":"Analysis of risk factors for low bone mineral density in inflammatory bowel disease","volume":"73","author":"Frei","year":"2006","journal-title":"Digestion"},{"issue":"10","key":"10.1016\/j.bone.2016.10.018_bb0330","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1359\/jbmr.090403","article-title":"A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis","volume":"24","author":"Eddleston","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.10.018_bb0335","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrendo.2011.233","article-title":"Bone, sweet bone\u2013osteoporotic fractures in diabetes mellitus","volume":"8","author":"Hamann","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"10.1016\/j.bone.2016.10.018_bb0340","doi-asserted-by":"crossref","first-page":"E1220","DOI":"10.1152\/ajpendo.00378.2011","article-title":"Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function","volume":"301","author":"Hamann","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bone.2016.10.018_bb0345","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2106\/JBJS.L.00285","article-title":"Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model","volume":"95","author":"Virk","year":"2013","journal-title":"J. Bone Joint Surg. Am."},{"issue":"8","key":"10.1016\/j.bone.2016.10.018_bb0350","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/jor.22636","article-title":"Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats","volume":"32","author":"Suen","year":"2014","journal-title":"J. Orthop. Res."},{"issue":"3","key":"10.1016\/j.bone.2016.10.018_bb0355","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00223-015-0085-3","article-title":"Effects of sclerostin antibody on the healing of femoral fractures in ovariectomised rats","volume":"98","author":"Liu","year":"2016","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bone.2016.10.018_bb0360","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.intimp.2014.11.010","article-title":"Systemic administration of sclerostin monoclonal antibody accelerates fracture healing in the femoral osteotomy model of young rats","volume":"24","author":"Feng","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"22","key":"10.1016\/j.bone.2016.10.018_bb0365","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2106\/JBJS.O.00171","article-title":"Systemic administration of sclerostin antibody enhances bone morphogenetic protein-induced femoral defect repair in a rat model","volume":"97","author":"Tinsley","year":"2015","journal-title":"J. Bone Joint Surg. Am."},{"issue":"2","key":"10.1016\/j.bone.2016.10.018_bb0370","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jor.22498","article-title":"Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model","volume":"32","author":"Alaee","year":"2014","journal-title":"J. Orthop. Res."},{"issue":"1","key":"10.1016\/j.bone.2016.10.018_bb0375","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jor.22186","article-title":"Effects of sclerostin antibody on healing of a non-critical size femoral bone defect","volume":"31","author":"Jawad","year":"2013","journal-title":"J. Orthop. Res."},{"issue":"2","key":"10.1016\/j.bone.2016.10.018_bb0380","first-page":"178","article-title":"Time-dependent effects of sclerostin antibody on a mouse fracture healing model","volume":"13","author":"Cui","year":"2013","journal-title":"J. Musculoskelet. Nueronal Interact."},{"issue":"3","key":"10.1016\/j.bone.2016.10.018_bb0385","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.1803","article-title":"Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus","volume":"28","author":"Hamann","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.10.018_bb0390","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2015.04.048","article-title":"Sclerostin antibody treatment improves fracture outcomes in a type I diabetic mouse model","volume":"82","author":"Yee","year":"2016","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.bone.2016.10.018_bb0395","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/jbmr.1984","article-title":"Sclerostin antibody stimulates bone regeneration after experimental periodontitis","volume":"28","author":"Taut","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.10.018_bb0400","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bone.2015.04.002","article-title":"Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis","volume":"76","author":"Chen","year":"2015","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.bone.2016.10.018_bb0405","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1096\/fj.14-265496","article-title":"Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse model","volume":"29","author":"Ren","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.bone.2016.10.018_bb0410","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.matbio.2015.12.009","article-title":"Sclerostin antibody (Scl-Ab) improves osteomalacia phenotype in dentin matrix protein 1(Dmp1) knockout mice with little impact on serum levels of phosphorus and FGF23","volume":"52\u201354","author":"Ren","year":"2016","journal-title":"Matrix Biol."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216303143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216303143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T09:27:44Z","timestamp":1536312464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328216303143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":82,"alternative-id":["S8756328216303143"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.10.018","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of anti-Sclerostin therapy in non-osteoporosis disease models","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}